Sweden
· Delayed Price · Currency is SEK Nanexa AB Company Description
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America.
The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances.
It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a depot drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a depot drug from lenalidomide for the treatment of multiple myeloma.
The company has collaborations with Novo Nordisk and AstraZeneca for the development of pharmaceutical products with active substances.
Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
| Country | Sweden |
| Founded | 2007 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 15 |
| CEO | David Westberg |
Contact Details
Address: Virdings Allé 2 Uppsala, 75450 Sweden | |
| Phone | 46 18 10 03 00 |
| Website | nanexa.com |
Stock Details
| Ticker Symbol | NANEXA |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0007074166 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David Westberg | Chief Executive Officer |
| Marten Rooth | Co-Founder and Chief Technology Officer |
| Anders Johansson | Co-Founder and Head of Intellectual Property |
| Cecilia Danckwardt-Lilliestrom | Chief Financial Officer |
| Mikael Asp | Head of QA and Special Advisor |
| Joel Hellrup | Head of Pharmaceutical Research & Development |
| Polla Rouf | Head of ALD Research & Development |
| Bridget Lacey B.Sc. | Chief Business Officer |
| Otto Skolling M.Sc | Director of Business Development |